Stock Price & Analysis

Innovative Opioid Solutions: Ensysce Biosciences is developing safer opioids using "clever chemistry" to reduce risks of overdose and abuse, addressing the ongoing opioid crisis while providing effective pain management for patients with severe conditions.

Regulatory Recognition: Their modified oxycodone has received FDA "Fast Track" and "Breakthrough Therapy" designations, highlighting its potential to improve patient safety and confidence in opioid use amidst strict regulations.

Trading Halt: Ensysce Biosciences (ENSC) has had its trading halted due to pending news.

Recent Developments: The company has recently announced a partnership with a specialty drug manufacturer and reported improved financial results, among other updates.

Marvell Technology Financial Results: Marvell Technology, Inc. shares surged 12.6% in pre-market trading after reporting third-quarter earnings of 43 cents per share and revenue of $1.52 billion, both exceeding analyst expectations.

Stock Movements: Several stocks experienced significant pre-market trading movements, with CN Energy Group gaining 151.8% and Oriental Rise Holdings dropping 44.4%, reflecting a mix of positive earnings reports and market reactions to recent announcements.

Lyft's Quarterly Performance: Lyft, Inc. shares surged 21.5% in pre-market trading after reporting quarterly losses of three cents per share and revenue of $1.52 billion, both exceeding analyst expectations.

Market Movements: Several stocks experienced significant pre-market trading fluctuations, with AtlasClear Holdings gaining 89.6% and Digital Turbine falling 41.1% following their respective earnings reports.